Status:
COMPLETED
Plasma Lipoprotein Response to Glucagon-like Peptide-2
Lead Sponsor:
University Health Network, Toronto
Conditions:
Hyperlipidemias
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
PHASE3
Brief Summary
Some of the fat (triglyceride) from the food humans eat gets stored in the bowel. This triglyceride can then be released into the blood when another meal is consumed or in response to hormones. How th...
Detailed Description
The lipoprotein response will be performed in 15 healthy individuals recruited by newspaper advertisements. Each subject will be their own control, receiving both placebo and teduglutide, administered...
Eligibility Criteria
Inclusion
- Men and women, aged 18 to 60 years.
- Body mass index 20 to 27 kg/m2
Exclusion
- Patients with active inflammatory bowel disease
- Patients with pre-existing Celiac disease, exocrine pancreatic insufficiency or small bowel malabsorption
- Patients with active bowel malignancy
- Patients with diabetes mellitus or known/ suspected motility disorders of the gut
- Patients with decompensated liver disease
- Patients on ezetimibe or bile acid sequestrants
- Patients who are pregnant or breastfeeding.
- Patients with renal disease.
- Patients on benzodiazepine.
- Unstable cardiac or respiratory disease
- Any changes to medication in the preceding month
Key Trial Info
Start Date :
September 21 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03422666
Start Date
September 21 2018
End Date
December 1 2021
Last Update
June 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Toronto General Hopital
Toronto, Ontario, Canada, M5G 2C4